Hong Kong – Sinopharm Group Co. Ltd. disclosed the principal unaudited results of its Shanghai-listed subsidiary, Sinopharm (CNCM LTD), for the six months ended 30 June 2026.

Revenue and Profitability • Revenue reached RMB 26.73 billion, a 4.27% year-on-year increase. • Total profit declined 6.83% to RMB 1.14 billion. • Net profit attributable to shareholders fell 7.25% to RMB 0.88 billion. • After excluding non-recurring items, attributable net profit decreased 5.55% to RMB 0.88 billion.

Earnings and Returns • Basic and diluted earnings per share stood at RMB 1.1660, down 7.25% from the prior-year period. • Weighted average return on net assets was 4.69%, 0.76 percentage point lower year on year; after excluding non-recurring items, the metric declined by 0.66 percentage point to 4.69%.

Balance-Sheet Positions • Total assets were RMB 36.04 billion as of 30 June 2026, a 1.76% decrease from year-end 2025. • Net assets attributable to shareholders edged up 1.43% to RMB 18.81 billion.

Cash Flow • Operating activities recorded a net cash outflow of RMB 2.63 billion, widening from the RMB 1.51 billion outflow in the same period last year.

The disclosed figures are unaudited and were released in accordance with Hong Kong Stock Exchange requirements and the Securities and Futures Ordinance.